Drug Profile
Research programme: cancer therapeutics - Yungjin Pharm
Alternative Names: YAC-1912; YPC-1811Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Yungjin Pharm Co
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Prostate cancer
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Cancer in South Korea
- 28 Feb 2020 No recent reports of development identified for research development in Prostate-cancer in South Korea
- 21 Jan 2016 Early research in Cancer in South Korea (unspecified route) (Yungjin Pharm's pipeline, January 2016)